Guarding a $2 billion franchise operation, Gilead hustles up its sNDA for Descovy. But will it work?
Gilead has two years to go as it works to transition patients from Truvada to Descovy before the older drug sees an onslaught of generics slice and dice the market.
But they aren’t wasting a day.
The big biotech said today that they will use a priority review voucher to hustle along the supplemental application to sell the drug to reduce the risk of infection among a vulnerable HIV-negative population. That will cut the review time down from 10 months to 6.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
